Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
e-REVRI
2023-505834-84-00Phase 3Authorised
- Sponsor
- LYSARC
- Start
- Feb 2025
- Modality
- T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, open-label trial of epcoritamab in Diffuse Large B-Cell Primary Central Nervous System Lymphoma and primary retinal lymphoma (PRL) (2 cohorts), sponsored by LYSARC. Primary endpoint: Best objective response rate (ORR) during the first 8 cycles in R/R PCNSL cohort (central review). Planned start Feb 2025; status: authorised.
02
Drugs
epcoritamab
03
Conditions
Diffuse Large B-Cell Primary Central Nervous System Lymphomaprimary retinal lymphoma (PRL)
Beyond the preview
Go deeper on 2023-505834-84-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-505834-84-00.